S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
OTCMKTS:LBTSF

Almirall Stock Forecast, Price & News

$15.30
0.00 (0.00 %)
(As of 10/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.30
$15.30
50-Day Range
$15.15
$15.30
52-Week Range
$15.30
$15.30
VolumeN/A
Average Volume1,433 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LBTSF News and Ratings via Email

Sign-up to receive the latest news and ratings for Almirall and its competitors with MarketBeat's FREE daily newsletter.


Almirall logo

About Almirall

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for the central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:LBTSF
CIK
N/A
Employees
1,787
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Almirall (OTCMKTS:LBTSF) Frequently Asked Questions

Is Almirall a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Almirall in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Almirall stock.
View analyst ratings for Almirall
or view top-rated stocks.

What stocks does MarketBeat like better than Almirall?

Wall Street analysts have given Almirall a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Almirall wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Almirall's stock been impacted by COVID-19 (Coronavirus)?

Almirall's stock was trading at $13.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LBTSF shares have increased by 17.7% and is now trading at $15.30.
View which stocks have been most impacted by COVID-19
.

Who are Almirall's key executives?

Almirall's management team includes the following people:
  • Dr. Jorge Gallardo Ballart, Chairman & Pres (Age 80, Pay $542.76k)
  • Mr. Gianfranco Nazzi, CEO & Exec. Director (Age 52)
  • Mr. Michael McClellan, Exec. VP of Fin., CFO & Member of Management Board (Age 50)
  • Mr. Joan Figueras Carreras, Gen. Counsel, Corp. Director, Vice Sec., Member of Mgmt. Board & Non-Voting Director
  • Mr. Eloi Crespo Cervera, Sr. VP of Industrial Operations & Member of Management Board
  • Mr. Alfredo Barón de Juan, Exec. VP of Global Commercial Operations & Member of Management Board
  • Dr. Francesca Domenech Wuttke Ph.D., Chief Digital Officer & Member of Management Board
  • Mr. Jordi Sabé Richer, Sr. VP of Corp. Devel. & Member of Management Board
  • Ms. Amita Kent, Sr. VP of Legal, Global Chief Compliance & Data Privacy Officer and Member of Management Board
  • Mr. Esteve Conesa Panicot, Sr. VP of HR & Member of Management Board

What is Almirall's stock symbol?

Almirall trades on the OTCMKTS under the ticker symbol "LBTSF."

How do I buy shares of Almirall?

Shares of LBTSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Almirall's stock price today?

One share of LBTSF stock can currently be purchased for approximately $15.30.

How many employees does Almirall have?

Almirall employs 1,787 workers across the globe.

What is Almirall's official website?

The official website for Almirall is www.almirall.com.

Where are Almirall's headquarters?

How can I contact Almirall?

Almirall's mailing address is Ronda General Mitre, 151, Barcelona, Catalonia 08022. The company can be reached via phone at 34 93 291 30 00.


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.